2. Academic Validation
  3. Protein disulfide isomerase in cardiovascular disease

Protein disulfide isomerase in cardiovascular disease

  • Exp Mol Med. 2020 Mar;52(3):390-399. doi: 10.1038/s12276-020-0401-5.
Bei Xiong 1 2,  Vishwanath Jha 1,  Jeong-Ki Min 3 4,  Jaehyung Cho 5
Affiliations

Affiliations

  • 1 Department of Pharmacology, University of Illinois-Chicago College of Medicine, Chicago, IL, 60612, USA.
  • 2 Department of Hematology, Zhongnan Hospital of Wuhan University, 430071, Wuhan, Hubei, P.R. China.
  • 3 Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
  • 4 Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon, Republic of Korea.
  • 5 Department of Pharmacology, University of Illinois-Chicago College of Medicine, Chicago, IL, 60612, USA. [email protected].
PMID: 32203104 DOI: 10.1038/s12276-020-0401-5
Abstract

Protein disulfide isomerase (PDI) participates in the pathogenesis of numerous diseases. Increasing evidence indicates that intravascular cell-derived PDI plays an important role in the initiation and progression of cardiovascular diseases, including thrombosis and vascular inflammation. Recent studies with PDI conditional knockout mice have advanced our understanding of the function of cell-specific PDI in disease processes. Furthermore, the identification and development of novel small-molecule PDI inhibitors has led into a new era of PDI research that transitioned from the bench to bedside. In this review, we will discuss recent findings on the regulatory role of PDI in Cardiovascular Disease.

Figures
Products